Skip to main content
PMC home page
Japanese Journal of Cancer Research : Gann logoLink to Japanese Journal of Cancer Research : Gann
. 1989 Feb;80(2):167–172. doi: 10.1111/j.1349-7006.1989.tb02285.x

Effects of the Plasma Concentration of 5‐Fluorouracil and the Duration of Continuous Venous Infusion of 5‐Fluorouracil with an Inhibitor of 5‐Fluorouracil Degradation on Yoshida Sarcomas in Rats

Setsuro Fujii 1, Yuji Shimamoto 1, Hideyuki Ohshimo 1, Takeshi Imaoka 1, Masaaki Motoyama 1, Masakazu Fukushima 1, Tetsuhiko Shirasaka 1
PMCID: PMC5917696  PMID: 2498251

Abstract

The correlations of the 5‐fluorouracil (5‐FU) level in the plasma and the duration of continuous 5‐FU infusion with the antitumor activity of 5‐FU on Yoshida sarcomas in rats were examined. The circadian variation in the plasma level of 5‐FU during continuous infusion was prevented by treatment with 3‐cyano‐2,6‐dihydroxypyridine (CNDP), which strongly inhibits 5‐FU degradation. On continuous venous infusion of 2 to 30 mg/kg of 5‐FU over 24 h with CNDP at a molar ratio of 1:10 into normal rats, the 5‐FU level in the blood was linearly proportional to the dose of 5‐FU. The optimum schedule for antitumor activity on Yoshida sarcomas in rats was found to be infusion of 5‐FU at 5 mg/kg over 24 h for 6 consecutive days, which gave a plasma 5‐FU level of 176 ng/ml. Continuous infusion of 5‐FU to give a plasma level of 300 ng/ml for 6 consecutive days from day 5 after implantation of tumor cells, when the tumors weighed about 1.0 g, resulted in complete regression of the tumors in all rats.

Keywords: Continuous venous infusion, 5‐Fluorouracil, Antitumor activity, Yoshida sarcoma, 5‐Fluorouracil degradation

Full Text

The Full Text of this article is available as a PDF (323.2 KB).

REFERENCES

  • 1. ) Byfield , J. E. , Frankel , S. S. and Hornbeck , C. L.Phase I and pharmacologic study of 72‐hour infused 5‐fluorouracil in man . Am. J. Clin. Oncol. , 8 , 429 – 440 ( 1985. ). [DOI] [PubMed] [Google Scholar]
  • 2. ) Shah , A. , MacDonald , W. , Goldie , J. , Gudauskas , G. and Brisebois , B.5‐FU infusion in advanced colorectal cancer:a comparison of three dose schedules . Cancer Treat. Rep. , 69 , 739 – 742 ( 1985. ). [PubMed] [Google Scholar]
  • 3. ) Sullivan , R. D. , Young , C. W. and Miller , E.The clinical effects of continuous administration of fluorinated pyrimidines (5 ‐ fluorouracil and 5 ‐ fluoro ‐ 2′‐ deoxyuridine) . Cancer Chemother. Rep. , 8 , 77 – 83 ( 1960. ). [PubMed] [Google Scholar]
  • 4. ) Lokich , J. , Fine , N. , Perri , J. and Bothe , A. , Jr.Protracted ambulatory venous infusion of 5‐fluorouracil . Am. J. Clin. Oncol. , 6 , 103 – 107 ( 1983. ). [PubMed] [Google Scholar]
  • 5. ) Caballero , G. A. , Ausman , R. K. and Quebbeman , E. J.Long‐term, ambulatory, continuous iv infusion of 5‐FU for the treatment of advanced adenocarcinomas . Cancer Treat. Rep. , 69 , 13 – 15 ( 1985. ). [PubMed] [Google Scholar]
  • 6. ) Drewinko , B. and Yang , L‐Y.Cellular basis for the inefficacy of 5‐FU in human colon carcinoma . Cancer Treat. Rep. , 69 , 1391 – 1398 ( 1985. ). [PubMed] [Google Scholar]
  • 7. ) Kawai , M. , Rosenfeld , J. , McCulloch , P. and Hillcoat , B. L.Blood levels of 5‐fluorouracil during intravenous infusion . Br. J. Cancer , 33 , 346 – 347 ( 1976. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8. ) Hillcoat , B. L. , McCulloch , P. B. , Figueredo , A. T. , Ehsan , M. H. and Rosenfeld , J. M.Clinical response and plasma levels of 5‐fluorouracil in patients with colonic cancer treated drug infusion . Br. J. Cancer , 38 , 719 – 724 ( 1978. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9. ) Gudauskas , G. and Goldie , J. H.The pharmacokinetics of high‐dose continuous 5‐fluorouracil infusions . Proc. Am. Assoc. Cancer Res. , 19 , C‐230 ( 1978. ). [Google Scholar]
  • 10. ) Fox , R. M. , Woods , R. L. , Tattersall , M. H. N. , Piper , A. A , and Sampson , D.Allopurinol modulation of fluorouracil tosicity . Cancer Chemother. Pharmacol , 5 , 151 – 155 ( 1981. ). [DOI] [PubMed] [Google Scholar]
  • 11. ) Howell , S. B. , Wung , W. E. , Taetle , R. , Hussain , F. and Romine , J. S.Modulation of 5‐fluorouracil toxicity by allopurinol in man . Cancer , 48 , 1281 – 1289 ( 1981. ). [DOI] [PubMed] [Google Scholar]
  • 12. ) Sampson , D. C. , Fox , R. M. , Tattersall , M. H. and Hensley , W. J.A rapid high‐performance liquid chromatographic method for quantitation of 5‐fluorouracil in plasma after continuous intravenous infusion . Ann. Clin. Biochem. , 19 , 125 – 128 ( 1982. ). [DOI] [PubMed] [Google Scholar]
  • 13. ) Hornbeck , C. L. , Floyd , R. A. , Byfield , J. E. , Griffiths , J. C. , Frankel , S. and Sharp , T. R.Cerebrospinal fluid versus serum concentrations of 5‐FU, allopurinol, and oxipurinol during treatment of metastatic brain cancer with 5‐FU infusion, allopurinol, and radiation . Cancer Treat. Rep. , 66 , 571 – 573 ( 1982. ). [PubMed] [Google Scholar]
  • 14. ) Boublil , J. L. , Milano , G. , Khater , R. , Bourry , J. , Thyss , A. , Bruneton , J. N. , Renee , N. , Philip , C. and Namer , M.Continuous 5‐day regional chemotherapy by 5‐fluorouracil in colon carcinoma: pharmacokinetic evaluation . Br. J. Cancer , 52 , 15 – 20 ( 1985. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15. ) Erlichman , C. , Fine , S. and Elhakim , T.Plasma pharmacokinetics of 5‐FU given by continuous infusion with allopurinol . Cancer Treat. Rep. , 70 , 903 – 904 ( 1986. ). [PubMed] [Google Scholar]
  • 16. ) Petit , E. , Milano , G. , Livi , F. , Thyss , A. , Bailleul , F. and Schneider , M.Orcadian rhythm‐varying plasma concentration of 5‐fluorouracil during five day continuous venous infusion at a constant rate in cancer patients . Cancer Res. , 48 , 1676 – 1679 ( 1988. ). [PubMed] [Google Scholar]
  • 17. ) Heggie , G. D. , Sommadossi , J‐P. , Cross , D. S. , Huster , W. J. and Diasio , R. B.Clinical pharmacokinetics of 5‐fluorouracil and its metabolites in plasma, urine and bile . Cancer Res. , 47 , 2203 – 2206 ( 1987. ). [PubMed] [Google Scholar]
  • 18. ) Hull , W. E. , Port , R. E. , Herrmann , R. , Britsch , B. and Kunz , W.Metabolites of 5‐fluorouracil in plasma and urine, as monitored by 19F nuclear magnetic response spectroscopy, for patients receiving chemotherapy with or without methotrexate pretreatment . Cancer Res. , 48 , 1680 – 1688 ( 1988. ). [PubMed] [Google Scholar]
  • 19. ) Floyd , R. , Griffiths , J. , Hornbeck , C. , Frankel , S. , Sharp , T. and Byfield , J.Total body clearance of infusional 5‐fluorouracil (5‐FU) . Proc. Am. Assoc. Cancer Res. , 21 , 395 ( 1980. ). [Google Scholar]
  • 20. ) Tatsumi , K. , Fukushima , M. , Shirasaka , T. and Fujii , S.Inhibitory effects of pyrimidine, barbituric acid and pyridine derivatives on 5‐fluorouracil degradation in rat liver extracts . Jpn. J. Cancer Res. , 78 , 748 – 755 ( 1987. ). [PubMed] [Google Scholar]
  • 21. ) Radzialowski , F. and Bousquet , W.Daily rhythmic variation in hepatic drug metabolism in rat and mouse . J. Pharmacol. Exp. Ther. , 163 , 229 – 238 ( 1968. ). [PubMed] [Google Scholar]
  • 22. ) Ensminger , W. D. , Rojowsky , A. , Raso , V. , Levin , D. C. , Glode , M. , Come , S. , Steele , G. and Frei , E. , III.A clinical pharmacological evaluation of hepatic arterial infusion of 5‐fluoro‐2′‐deoxyuridine and 5‐fluorouracil . Cancer Res. , 38 , 3784 – 3792 ( 1978. ). [PubMed] [Google Scholar]
  • 23. ) Seifert , P. , Baker , L. H. , Reed , M. L. and Vaitkevicius , V. K.Comparison of continuously infused 5‐fluorouracil with bolus injection in treatment of patients with colorectal adenocarcinoma . Cancer , 36 , 123 – 128 ( 1975. ). [DOI] [PubMed] [Google Scholar]

Articles from Japanese Journal of Cancer Research : Gann are provided here courtesy of Wiley

RESOURCES